This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adenosine Therapeutics Engages Needham & Company To Explore Strategic Options For Phase III Cardiac Stress Agent

CHARLOTTESVILLE, Va., April 1, 2013 /PRNewswire/ --  Adenosine Therapeutics, LLC, a drug discovery and development company founded in 1999, announced today that it has engaged Needham & Company to explore strategic options for Stedivaze®, a highly selective adenosine A2A agonist being developed as a pharmacological stress agent for use in Myocardial Perfusion Imaging.

"We are seeking regional or global collaborators to rapidly conclude our Phase 3 clinical trials, which are more than halfway complete, and to pursue the approval, distribution, and marketing of Stedivaze®," said Adenosine Therapeutics Co-Founder and CEO Robert Capon. "Clinical trial data to date suggests Stedivaze® has the potential to demonstrate equivalent efficacy, compared to the standard of care, plus best-in-class product attributes, with the potential to expand the market for Cardiac Stress Agents."

"Stedivaze® has a strong patent estate with a long life," continued Robert Capon, "The pharmacological stress agent market is established, large (presently over $700 million in the United States), and growing. We believe that, with its potential best-in-class product characteristics, strong patent estate, and a large and growing market, that Stedivaze® represents an exceptional opportunity for the right partner. We are pleased to be working with Needham and Company to find such partner for this late-stage Specialty Pharma opportunity."

Adenosine Therapeutics, LLC is a drug discovery and development company founded in 1999. Adenosine Therapeutics holds the exclusive, worldwide license to the investigational compound apadenoson, the active pharmaceutical ingredient of Stedivaze®. The company re-acquired the exclusive, worldwide license to Stedivaze® on December 31, 2012. Two Phase 3 clinical trials for Stedivaze® are 52% complete.  The company is headquartered in Charlottesville, Virginia.

Needham & Company, LLC, a wholly owned subsidiary of The Needham Group, Inc., is a privately held, full-service investment bank that has focused exclusively on growth companies since it was founded 28 years ago. It concentrates on private companies and on public companies that have market capitalizations of up to $5 billion, and provides its clients with the resources to achieve their financing and strategic objectives. The Firm has capital raising expertise in IPOs, follow-on public equity offerings, confidentially marketed equity offerings, and private placements and in Mergers & Acquisitions and Corporate & Venture Services (including share repurchases). In addition to investment banking, Needham's activities include institutional sales and trading and asset management. To serve its institutional clients, Needham & Company, LLC produces comprehensive equity research on more than 350 companies in clean technology and industrial growth, communications and enterprise infrastructure, consumer, healthcare, semiconductors and semiconductor equipment, and software. The firm is headquartered in New York City with offices in Boston, MA, Menlo Park, CA, and San Francisco, CA. Needham & Company, LLC is a member of FINRA, SIPC & SIFMA.

Contact: Robert Capon, Chief Executive Officer, (434) 466-7812

SOURCE Adenosine Therapeutics, LLC

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 -13.76 -0.08%
S&P 500 1,983.04 +3.12 0.16%
NASDAQ 4,748.2780 -0.0830 -0.00%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs